|View printer-friendly version|
The abstract presentation, entitled, “Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results,” will be presented as part of the Advances in Retinal Gene Therapy and Stem Cells Session on
- The poster presentation, entitled, “Transplantation of human embryonic stem cell derived retinal tissue in the subretinal space of immunodeficient rats with retinal degeneration (RD),” will be presented as part of the Animal Models for Visual Disease and Restoration Session on
April 30, 2019between 8:45am to 10:30am EDT in Session Number 332 by Igor Nasonkin, PhD, Principal Investigator, Director of Research & Development at BioTime, Inc.(Posterboard Number: 3109 - A0500).
- The poster presentation, entitled, “Evaluation of selected Human Embryonic Stem Cell Lines for differentiation to three-dimensional retinal tissue (organoids) for cell therapies of retinal degenerative conditions,” will be presented as part of the Stem Cells and Retinal Organoids: Disease modeling Session on
April 30, 2019between 8:45am to 10:30am EDT in Session Number 323 by Ratnesh Singh, PhD, Senior Scientist at BioTime, Inc.(Posterboard Number: 2873 - A0044).
OpRegen® is a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, the leading cause of adult blindness in the developed world. OpRegen® consists of a suspension of retinal pigment epithelial (RPE) cells delivered subretinally as an intraocular injection. RPE cells are essential components of the back lining of the retina and function to help nourish the retina including photoreceptors. OpRegen® has been granted Fast Track designation from the U.S. Food and Drug Administration. OpRegen® is a registered trademark of
BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime’s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime’s lead cell delivery clinical program is Renevia®, an investigational medical device being developed as an alternative for whole adipose tissue transfer procedures. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn,
Solebury Trout IR